Skip to content
Angion Biomedica Corp

Angion Biomedica Corp

ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS

  • about
    • executive management
    • scientific advisory board
    • board of directors
  • our science
    • organ fibrosis
    • HGF/c-met pathway
  • pipeline
    • ANG-3070
    • ANG-3777
    • ROCK2 Inhibitor
    • CYP11B2 Inhibitor
  • Investors
    • stock information
      • stock quote & chart
      • historic price lookup
    • analyst coverage
    • press releases
    • events & presentations
    • sec filings
    • governance
    • investor resources
      • investor contact
      • investor FAQs
      • email alerts
  • publications
  • careers
  • contact

Author: David Miller

May 17, 2022May 17, 2022

ANG-3070 is a Highly-Selective, Orally-Available TKI in Development for Pulmonary and Renal Fibrosis

Posted in angion publications
November 5, 2021November 5, 2021

Phase 2 Study Design to Evaluate Safety and Efficacy of the Tyrosine Kinase Inhibitor ANG-3070 in Patients with Primary Proteinuric Kidney Disease

Posted in angion publications
November 4, 2021November 4, 2021

Effect of ANG-3070 in the Passive Heymann’s Nephritis Rat Model of Primary Proteinuric Kidney Disease

Posted in angion publications
November 4, 2021November 4, 2021

Effects of ANG-3070 in a Mouse Model of Alport Syndrome

Posted in angion publications
November 4, 2021November 4, 2021

Effect of ANG-3070 in the Unilateral Ureteral Obstruction Mouse Model of Renal Fibrosis

Posted in angion publications
June 4, 2021November 5, 2021

Costs in the Year Following Deceased Donor Kidney Transplantation: Relationships with Renal Function and Graft Failure

Posted in angion publications
January 16, 2021February 5, 2021

Stay tuned for future events

Posted in events
October 30, 2020February 5, 2021

Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery–Associated Acute Kidney Injury

Posted in angion publications
October 22, 2020February 5, 2021

The Effect of ANG-3777 on the Growth of c-Met Expressing Tumor Cells in Immunocompromised Mice

Posted in angion publications
October 22, 2020February 5, 2021

Defining a Clinically-Meaningful Difference (MCMD) in Estimated Glomerular Filtration Rate (eGFR) for Kidney Transplantation

Posted in angion publications

Posts navigation

Older posts

CATEGORIES

  • RSL-HGF
  • RSL-ALI
  • Fibrosis
  • ROCKi
  • angion publications
  • RSL-AKI
  • events

CORPORATE ADDRESS

51 Charles Lindbergh Boulevard
Uniondale, NY 11553

Navigation

  • home
  • about
  • our science
  • pipeline
  • investors
  • publications
  • careers
  • contact

© 2022 Angion. All Rights Reserved.
Legal and Privacy Policy

NEW YORK | BOSTON | AUSTRALIA